Abstract No.	Session Theme		Date & Time	Room	Title	Country
276	Dyslipidemia	MO-1-1	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Detection of monogenic familial hypercholesterolaemia using a novel genotyping technique - report from implementation and pilot testing phase	Czechia
262	Dyslipidemia	MO-1-2	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Apolipoprotein CIII deficiency inhibits cholesterol diet- induced hyperlipidemia and atherosclerosis in knockout rabbits	China
40	Dyslipidemia	MO-1-3	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Association of kidney function with levels of serum lathosterol and campesterol: The CACHE study CKD analysis	Japan
102	Dyslipidemia	MO-1-4	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Relationship between diabetes and serum lathosterol and campesterol levels: The CACHE study DM analysis	Japan
208	Dyslipidemia	MO-1-5	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	CREB3L3 protects atherosclerosis through increased lipolysis and inhibition of SREBP	Japan
268	Dyslipidemia	MO-1-6	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Malaria parasites hijack host CD36 from host platelets via exosomes to capture HDL for their proliferation.	Japan
55	Dyslipidemia	MO-1-7	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 2 (ICC Kyoto Room A)	Genome-wide association study of CRP identified apolipoprotein D as a novel anti-inflammatory apolipoprotein.	Japan
126	Pathogenesis	MO-2-1	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Accumulation of DNA damage promotes atherosclerosis by provoking inflammatory responses via cGAS-STING activation	Japan
39	Pathogenesis	MO-2-2	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Protective function of omentin in angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein-E knockout mice	Japan

Abstract No.	Session Theme		Date & Time	Room	Title	Country
99	Pathogenesis	MO-2-3	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Type I interferon signaling promotes aberrant inflammation in macrophage derived from Werner syndrome-specific iPSCs	Japan
97	Pathogenesis	MO-2-4	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)		Discovery of MHC Class-II restricted immunodominant T cell epitopes in human atherosclerosis-related autoantigen Apolipoprotein B 1	USA
110	Pathogenesis	MO-2-5	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	, , ,	Cholesterol-dominant steatohepatitis was accompanied with cardiac inflammation and dysfunction, which were Suppressed by pemafibrate	Japan
197	Pathogenesis	MO-2-6	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Development and Application of Engineered Vascular Tissues	UK
184	Pathogenesis	MO-2-7	Oct. 25 (Mon.) 15:05-15:55 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Cigarette smoke induced atherosclerotic plaques drive aortic wall degeneration and abdominal aortic aneurysms.	Japan
158	Epidemiology	MO-3-1	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)		Lifetime Risk of Cardiovascular Disease Death According to Composite Risk Factors: A Pooled Analysis of Data From the Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Study	Japan
149	Epidemiology	MO-3-2	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 1 (ICC Kyoto Annex Hall)	Lipoprotein(a) is associated with incidence but not progression of aortic valve calcium	Netherland s
248	Epidemiology	MO-3-3	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)		Association of Lower Coronary Heart Disease Risk with Higher Intake of Taurine and Magnesium through World-Wide 24-hour Urine Analysis and Comparison of Japanese and Mediterranean Diet with Euro-Western Diet.	Japan
133	Epidemiology	MO-3-4	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 1 (ICC Kyoto Annex Hall)	High Plasma Levels of Follistatin-like Protein 1 (FSTL1) in Patients with Coronary Artery Disease	Japan

Abstract No.	Session Theme		Date & Time	Room	Title	Country
288	Epidemiology	MO-3-5	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 1 (ICC Kyoto Annex Hall)	Increases in epicardial adipose tissue volume and density calculated by artificial intelligence-assisted measuring method in relation to obesity, aging, insulin resistance and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus	Japan
56	Epidemiology	MO-3-6	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 1 (ICC Kyoto Annex Hall)	Relationship between Statin Use and the Risk of Falls or Muscle Weakness in Subjects with Diabetes	Japan
261	Epidemiology	MO-3-7	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 1 (ICC Kyoto Annex Hall)	INVESTIGATION ON THE RELATIONSHIP OF FISH INTAKE AND ITS METABOLITES WITH RISK FACTORS OF METABOLIC SYNDROME: INTERLIPID METABOLOME -WIDE ASSOCIATION STUDY	Japan
239	Prevention	MO-4-1	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Skeletal muscle-specific forkhead box protein-O1 overexpression suppresses atherosclerosis progression in apolipoprotein E-knockout mice	Japan
269	Prevention	MO-4-2	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Familial hypercholesterolemia in Portugal - lipid- lowering strategies and cardiovascular disease risk	Portugal
103	Prevention	MO-4-3	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Impact of lifestyle changes on diabetes mellitus atherosclerosis risk management influenced by COVID-19 pandemic measures in Japan	Japan
204	Prevention	MO-4-4	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Clinical impact of perivascular fat attenuation index using coronary computed tomography angiography for the progression of coronary atherosclerosis in asymptomatic diabetic patients	Japan
52	Prevention	MO-4-5	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Mortality Risk Associated with Cessation of Renin- Angiotensin-Aldosterone Inhibitors in Heart Failure Patients with Hyperkalemia: A Real-world study from Japanese Nationwide Administrative Database	Japan
125	Prevention	MO-4-6	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Development of the novel diagnostic miRNA markers for diabetes complications using insulin resistance-specific circulating miRNAs and their predicted target genes	Japan

Abstract No.	Session Theme		Date & Time	Room	Title	Country
196	Withdraw		Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 2 (ICC Kyoto Room A)	Does low glycemic index diet superior than routine diet to control blood inflammation state and lipid parameters in patients with coronary artery disease?	Uzbekistan
71	Therapeutics	MO-5-1	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Effect of probucol on atherosclerotic cardiovascular events in Asian patients with coronary artery disease: Integrated analysis of PROSPECTIVE and IMPACT	Japan
156	Therapeutics	MO-5-2	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Effects of pemafibrate, a selective PPARa modulator (SPPARMa), on neutrophil-lymphocyte ratio (NLR): a pooled-analysis from 6 randomized, double-blind, placebo-controlled trials	Japan
96	Therapeutics	MO-5-3	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	LONG-TERM EFFICACY OF LIPOPROTEIN APHERESIS AND LOMITAPIDE IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HoFH): A CROSS-NATIONAL RETROSPECTIVE SURVEY	France
314	Therapeutics	MO-5-4	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Long-chain monounsaturated fatty acids improve endothelial function with altering microbial flora	Japan
310	Therapeutics	MO-5-5	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	A Novel Senolytic Drug, Seno-7284 Ameliorates Agerelated Cardiometabolic Diseases	Japan
209	Therapeutics	MO-5-6	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	A New Therapeutic Modality for Coronary Artery Disease: Mitochondria-Rich Extracellular Vesicles From Stem Cell-Derived Cardiomyocytes Restore the Energetics of Myocardium	USA
286	Therapeutics	MO-5-7	Oct. 26 (Tue.) 15:30-16:20 (Japan Time)	Room 3 (ICC Kyoto Room B-1)	Computational identification of Myricetin-3-0-galactoside belonging to Argania Spinosa L. as potent PCSK9 inhibitor	Morocco